drugset / Trial / NCT01176032
ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess efficacy of aliskiren for reducing circulating levels of biomarkers of left ventricular (LV) remodeling associated with LV hypertrophy (LVH) in hypertensive patients.
Timeline
- Start
- 2010-06
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aliskiren | Small molecule | 300 mg | — |
| Comparator | Losartan | Other / unclassified | 100 mg | — |
| Background | Amlodipine | Other / unclassified | 10 mg | — |
| Background | Hydrochlorothiazide | Unknown | 12.5 mg | — |